Arch Therapeutics Inc (ARTH): Price and Financial Metrics
ARTH Price/Volume Stats
| Current price | $0.74 | 52-week high | $18.00 |
| Prev. close | $0.75 | 52-week low | $0.17 |
| Day low | $0.74 | Volume | 2,300 |
| Day high | $0.74 | Avg. volume | 4,210 |
| 50-day MA | $0.78 | Dividend yield | N/A |
| 200-day MA | $2.46 | Market Cap | 3.51M |
ARTH Stock Price Chart Interactive Chart >
Arch Therapeutics Inc (ARTH) Company Bio
Arch Therapeutics, Inc. operates as a life science medical device company. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. Its primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Latest ARTH News From Around the Web
Below are the latest news stories about Arch Therapeutics Inc that investors may wish to consider to help them evaluate ARTH as an investment opportunity.
Arch Therapeutics Completes Leadership Team with Appointment of Dan Yrigoyen as Vice President of SalesMedical Industry Veteran with Proven Track Record to Drive Commercialization Effort FRAMINGHAM, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that Dan Yrigoyen has joined the organization as Vice President of Sales. Mr. Yrigoyen will lead the Company’s national commercialization effort with a focus on revenue generation and channel development. Mr. Yr |
Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021FRAMINGHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will present at the upcoming Ladenburg Thalmann 2021 Healthcare Conference, which shall be held July 13-14, 2021. Chief Executive Officer, Terry Norchi, MD, is scheduled to provide a corporate update and, along with Chief Financial Officer, Mike Abrams, participate in a subsequent quest |
Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presented virtually at the upcoming LD Micro Invitational XI event. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Mike Abrams, are scheduled to present via webcast, which will be available on-demand as of 4:15 PM ET, Thursday, Jun. 10, 2021. You m |
Arch Therapeutics Appoints Michael S. Abrams its Chief Financial OfficerCompany Prepares for Next Stage of GrowthFRAMINGHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has appointed Michael S. Abrams its Chief Financial Officer effective May 10, 2021. In alignment with the Company’s succession plan, Mr. Abrams joins Arch’s financial team today, one week before assuming the role currently held by the Company’s Chief Financial Officer, Richard Davis. Mr. Davis will remain with the Company during a Transition Period, which will end on June 30, 2021, after which he will support the Company in a consulting role through December 31, 2021. Mr. Abrams has over 25 years of experience as a Chief Financial Officer... |
Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021Management to provide corporate update on Dermal Sciences and BioSurgeryFRAMINGHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), innovator of AC5® Advanced Wound System and other self-assembling Dermal Sciences and BioSurgery devices, announced today that it will be presenting at the H.C. Wainwright Global Life Sciences Conference, which will be held March 9-10, 2021. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Richard Davis, are scheduled to present via webcast and be available for meetings. The webcast will be available on-demand starting at 7:00 A.M. EST, Tuesday, March 9, 2021. You may access the live webcast by clicking here: webcast. Attendees may find conference information and registe... |
ARTH Price Returns
| 1-mo | 11.28% |
| 3-mo | N/A |
| 6-mo | -61.46% |
| 1-year | -67.83% |
| 3-year | -96.15% |
| 5-year | -98.58% |
| YTD | -89.78% |
| 2023 | 39.23% |
| 2022 | -72.63% |
| 2021 | -36.62% |
| 2020 | -39.94% |
| 2019 | -52.91% |
Loading social stream, please wait...